Back

Individuals who were mildly symptomatic following infection with SARS-CoV-2 B.1.1.28 have neutralizing antibodies to the P.1 variant.

Mendes-Correa, M. C.; Vilas-Boas, L. S. S.; Bierrenbach, A. L.; Vincente de Paula, A.; Tozetto-Mendoza, T. R.; Leal, F. E.; Freire, W.; Paiao, H. G. O.; Ferraz, A. d. B. C.; Witkin, S. S.

2021-05-17 infectious diseases
10.1101/2021.05.11.21256908 medRxiv
Show abstract

ObjectivesTo evaluate if antibodies induced by infection with a different SARS-CoV-2 virus strain neutralize the P.1 variant. MethodsConvalescent sera from 60 individuals following a documented SARS-CoV-2 infection were assayed for neutralizing antibody titer against both strains. ResultsFifty-six and 50 sera were positive for neutralizing antibodies against the ancestral and P.1 strains, respectively. Neutralization titers were higher against the ancestral strain, but in the majority of patients differences did not differ by more than a single dilution. ConclusionsNeutralizing antibodies that were generated following infection with SARS-CoV-2 B.1.1.28 were effective in vitro, against the SARS-CoV-2 P.1. variant.

Matching journals

The top 9 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.